CK 0801

Drug Profile

CK 0801

Alternative Names: CK0801

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellenkos; University of Texas M. D. Anderson Cancer Center
  • Developer Cellenkos; University of Texas Health Science Center at Houston; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antianaemics; Antihyperglycaemics; Antipsoriatics; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Graft-versus-host disease
  • Preclinical Aplastic anaemia; Autoimmune disorders; Multiple sclerosis; Psoriasis; Type 1 diabetes mellitus
  • Research Guillain-Barre syndrome

Most Recent Events

  • 22 Jun 2018 Cellenkos and University Of Texas Health Science Center at Houston agree to co-develop CK 0801 for Guillain-Barre syndrome
  • 22 Jun 2018 Early research in Guillain-Barre syndrome in USA (unspecified route)
  • 10 Jun 2018 US FDA approves IND application for CK 0801 in Bone marrow disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top